Microvascular complications: Retinopathy and nephropathy

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 4, 2001, Pages 833-856

  Skyler, J S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN;

BLINDNESS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LASER COAGULATION; META ANALYSIS; MICROALBUMINURIA; OPHTHALMOSCOPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST;

EID: 0035159384     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70218-8     Document Type: Article

References (86)

1. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
2. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
3. Greater reduction of urinary albumin excretion in hypertensive type 2 diabetic patients with incipient nephropathy by lisinopril than by nifedipine
4. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria
5. Position statement: Diabetic retinopathy
6. Position statement: Diabetic nephropathy
7. Diabetic nephropathy: Its relationship to hypertension and means of pharmacological intervention
8. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy
9. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes
10. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus
11. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
12. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
13. Pathogenesis, prevention, and treatment of diabetic nephropathy
14. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure: The Italian Microalbuminuria Study Group in IDDM
15. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
16. The effect of intensive treatment of diabetes on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial
17. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
18. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial
19. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial
20. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
21. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: Four-year results of a randomized trial (report #5)
22. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: Results of a randomized study (report #3)
23. Photocoagulation treatment of diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings: DRS report number 8
24. Preliminary report on effects of photocoagulation therapy
25. Photocoagulation for diabetic macular edema: ETDRS report number 1
26. Photocoagulation for diabetic macular edema: ETDRS report number 4
27. Early photocoagulation for diabetic retnopathy: ETDRS report number 9
28. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: The European Study for the Prevention of Renal Disease in type 1 Diabetes (ESPRIT)
29. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
30. Effect of improved metabolic control on loss of kidney function in type I (insulin-dependent) diabetic patients: An update of the Steno studies
31. Reversal of lesions of diabetic nephropathy after pancreas transplantation
32. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes
33. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
34. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
35. Prevention of end-stage renal disease due to type 2 diabetes
36. Progression of diabetic nephropathy
37. An effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis
38. Hyperglycemia and microvascular and macrovascular disease in diabetes
39. Epidemiology of proliferative diabetic retinopathy
40. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus
41. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy
42. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy
43. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials
44. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus
45. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
46. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
47. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
48. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
49. Nephropathy and hypertension in diabetes
50. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria
51. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria
52. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
53. The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys to diabetic patients
54. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria
55. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria
56. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas
57. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy
58. The renal hemodynamic basis of diabetic nephropathy
59. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy
60. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: Results of a randomized controlled trial
61. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
62. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
63. Diabetic nephropathy and arterial hypertension: The effect of antihypertensive treatment
64. Effect of antihypertensive treatment on kidney function in diabetic nephropathy
65. Dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis
66. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
67. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: A randomized, controlled trial
68. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow-up study
69. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients
70. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
71. Blood pressure in diabetic nephropathy - Current controversies
72. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus
73. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients
74. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: Results of a 4-year, prospective, randomized study
75. Diabetic complications: Glucose control is important
76. Sustained reduction in albuminuria six years after the diabetes control and complications trial
77. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
78. Diagnosis of diabetic eye disease
79. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
80. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
81. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
82. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
83. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
84. Effects of cilazapril and and amlodipine on kidney function in hypertensive NIDDM patients
85. Effect of captopril on progression to clinical proteinuria in patients with insulin dependent diabetes mellitus and microalbuminuria
86. Meta-analysis of effects of intensive blood glucose control on late complications of type 1 diabetes